Prevalence of Charles Bonnet syndrome in patients with age-related macular degeneration: systematic review and meta-analysis.
Charles Bonnet syndrome
age-related macular degeneration
prevalence
systematic review
visual hallucinations
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
11
05
2019
accepted:
03
10
2019
pubmed:
28
10
2019
medline:
23
1
2021
entrez:
27
10
2019
Statut:
ppublish
Résumé
Age-related macular degeneration (AMD) is the most common cause of visual impairment in the developed world. A number of patients experience complex lifelike visual experiences-Charles Bonnet syndrome (CBS). In this systematic review, our aim was to provide an overview of the CBS literature in relation to AMD, to determine the prevalence of CBS in patients with AMD and to provide an overview of associated demographical and clinical aspects. We searched the literature databases PubMed/MEDLINE, EMBASE, Web of Science, the Cochrane Central, and PsycINFO on 22 March 2019 for studies evaluating the prevalence of CBS in patients with AMD. Two independent authors extracted the data and evaluated risk of bias. Studies were reviewed qualitatively in the text and quantitatively in a meta-analysis including subgroup analyses for differences between demographic and clinical factors. We identified 18 studies with data on >4303 patients with AMD. We found an overall prevalence of CBS of 15.8% (95% confidence interval: 11.0%-21.2%). When looking at consecutively recruited patients with neovascular AMD from the clinic, prevalence of CBS was 7.2% (95% confidence interval: 4.3%-10.6%). Among visitors to visual rehabilitation centres, prevalence of CBS was 31.6% (95% confidence interval: 21.7%-42.3%). Taken together, we find that CBS is rather common in patients with AMD.
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-131Informations de copyright
© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Abbott EJ, Connor GB, Artes PH & Abadi RV (2007): Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci 48: 1416-1423.
Agron E, Clemons TE & Chew EY (2016): Charles bonnet syndrome in participants of the age-related eye disease study 2 (AREDS2). Invest Ophthalmol Vis Sci 57: 2662.
Alamri SH (2018): A low dose of risperidone resolved Charles Bonnet syndrome after an unsuccessful trial of quetiapine: a case report. Neuropsychiatr Dis Treat 14: 809-811.
Anderson D, Pankow L & Luchins D (2004): The possible role of vision rehabilitation in the treatment of visual hallucinations in the elderly. Top Geriatr Rehabil 20: 204-211.
Barendregt JJ, Doi SA, Lee YY, Norman RE & Vos T (2013): Meta-analysis of prevalence. J Epidemiol Community Health 67: 974-978.
Billings FT & Pitt J (2008): Charles Bonnet low visions. Trans Am Clin Climatol Assoc 119: 225-226.
Bonnet C (1769): Essai Analytique sur les Faculties de l'Ame. Copenhaven & Geneva, Tom, 1769.
Boxerman H, Wittich W & Overbury O (2014): Charles Bonnet syndrome in older adults with age-related macular degeneration: Its relationship to depression and mild cognitive impairment. Br J Vis Impair 22: 19-30.
Brown GC & Murphy RP (1992): Visual symptoms associated with choroidal neovascularization. Photopsias and the Charles Bonnet syndrome. Arch Ophthalmol 110: 1251-1256.
Coletti Moja M, Milano E, Gasverde S, Gianelli M & Giordana MT (2005): Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci 26: 168-170.
Egger M, Davey Smith G, Schneider M & Minder C (1997): Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
Flaxman SR, Bourne RRA, Resnikoff S, et al. (2017): Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 5: e1221-e1234.
Gilmour G, Schreiber C & Ewing C (2009): An examination of the relationship between low vision and Charles Bonnet syndrome. Can J Ophthalmol 44: 49-52.
Gordon KD (2016): Prevalence of visual hallucinations in a national low vision client population. Can J Ophthalmol 51: 3-6.
Hedges TR Jr (2007): Charles Bonnet, his life, and his syndrome. Surv Ophthalmol 52: 111-114.
Higgins JPT & Green S, eds. (2011): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. Available at: https://www.handbook.cochrane.org. Accessed November 9th, 2018.
Higgins JP, Thompson SG, Deeks JJ & Altman DG (2003): Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
Holroyd S, Rabins PV, Finkelstein D, Nicholson MC, Chase GA & Wisniewski SC (1992): Visual hallucinations in patients with macular degeneration. Am J Psychiatry 149: 1701-1706.
Holz FG, Strauss EC, Schmitz-Valckenberg S & van Lookeren Campagne M (2014): Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 121: 1079-1091.
Hou Y & Zhang Y (2012): The prevalence and clinical characteristics of Charles Bonnet syndrome in Chinese patients. Gen Hosp Psychiatry 34: 566-570.
Jacob A, Prasad S, Boggild M & Chandratre S (2004): Charles Bonnet syndrome-elderly people and visual hallucinations. BMJ 328: 1552-1554.
Khan JC, Shahid H, Thurlby DA, Yates JR & Moore AT (2008): Charles Bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end-stage disease. Ophthalmic Epidemiol 15: 202-208.
Lang UE, Stogowski D, Schulze D, Domula M, Schmidt E, Gallinat J, Tugtekin SM & Felber W (2007): Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol 21: 553-555.
Lannon SP, Stevenson MR, White ST, Logan JF, Reinhardt-Rutland AH & Jackson AJ (2006): Visual hallucinations in patients with age-related macular degeneration (AMD). Vis Impair Res 8: 9-16.
Leandro JE, Beato J, Pedrosa AC, Pinheiro-Costa J, Falcão M, Falcão-Reis F & Carneiro ÂM (2017): The Charles Bonnet syndrome in patients with neovascular age-related macular degeneration: association with proton pump inhibitors. Invest Ophthalmol Vis Sci 58: 4138-4142.
Lewis S & Clarke M (2001): Forest plots: trying to see the wood and the trees. BMJ 322: 1479-1480.
Liu Y, Wen F, Huang S, Luo G, Yan H, Sun Z & Wu D (2007): Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 245: 1441-1445.
Menon GJ, Rahman I, Menon SJ & Dutton GN (2003): Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome. Surv Ophthalmol 48: 58-72.
Mitrut I, Chua P, Aslam T, Vani A, Ambrecht AM & Dhillon B (2010): Short-term changes of visual hallucinations after intravitreal injection of ranibizumab in neovascular age-related macular degeneration. Eye 24: 1825.
Moher D, Liberati A, Tetzlaff J, Altman DG & PRISMA Group (2009): Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
de Morsier G (1967): Le Syndrome de Charles Bonnet. Ann Med Psych 128: 677-702.
Nalcaci S, İlim O, Oztas Z, Akkin C, Acarer A, Afrashi F & Mentes J (2016): The prevalence and characteristics of Charles Bonnet syndrome in Turkish patients with retinal disease. Ophthalmologica 236: 48-52.
Nixon PA & Mason JO 3rd (2006): Visual hallucinations from age-related macular degeneration. Am J Med 119: e1-e2.
Roh M, Selivanova A, Shin HJ, Miller JW & Jackson ML (2018): Visual acuity and contrast sensitivity are two important factors affecting vision-related quality of life in advanced age-related macular degeneration. PLoS ONE 13: e0196481.
Sedeh FB, Scott DAR, Subhi Y & Sørensen TL (2017): Prevalence of neovascular age-related macular degeneration and geographic atrophy in Denmark. Dan Med J 64: A5422.
Singh A & Sørensen TL (2011): Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration. Br J Ophthalmol 95: 291-292.
Singh A & Sørensen TL (2012): The prevalence and clinical characteristics of Charles Bonnet Syndrome in Danish patients with neovascular age-related macular degeneration. Acta Ophthalmol 90: 476-480.
Singh A, Subhi Y & Sørensen TL (2014): Low awareness of the Charles Bonnet syndrome in patients attending a retinal clinic. Dan Med J 61: A4770.
Stroup DF, Berlin JA, Morton SC, et al. (2000): Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
Subhi Y, Henningsen GØ, Larsen CT, Sørensen MS & Sørensen TL (2014): Foveal morphology affects self-perceived visual function and treatment response in neovascular age-related macular degeneration: a cohort study. PLoS ONE 9: e91227.
Tan CS, Lim VS, Ho DY, Yeo E, Ng BY & Au Eong KG (2004): Charles Bonnet syndrome in Asian patients in a tertiary ophthalmic centre. Br J Ophthalmol 88: 1325-1329.
Terao T (1998): Effect of carbamazepine and clonazepam combination on Charles Bonnet Syndrome: a case report. Hum Psychopharmacol Clin Exp 13: 451-453.
Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL & Zitman FG (1996): Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 347: 794-797.
Vlassoff C (2007): Gender differences in determinants and consequences of health and illness. J Health Popul Nutr 25: 47-61.
Vojniković B, Radeljak S, Dessardo S, Zarković-Palijan T, Bajek G & Linsak Z (2010): What associates Charles Bonnet syndrome with age-related macular degeneration? Coll Antropol 34(Suppl 2): 45-48.
Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y & Du L (2015): The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 8: 2-10.
Zhang H, Liu ZL, Sun P & Gu F (2012): Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration. Acta Ophthalmol 90: e647-e648.